Cargando…

Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank

BACKGROUND: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a newly defined condition encompassing hepatic steatosis and metabolic dysfunction. However, the relationship between MAFLD and multi-system diseases remains unclear, and the time-dependent sequence of these diseases require...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Yu, Li, Dongze, You, Yi, Yu, Jing, Jiang, Wenli, Liu, Yi, Zeng, Rui, Wan, Zhi, Lei, Yi, Liao, Xiaoyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590000/
https://www.ncbi.nlm.nih.gov/pubmed/37864216
http://dx.doi.org/10.1186/s12916-023-03080-6
_version_ 1785123905560641536
author Jia, Yu
Li, Dongze
You, Yi
Yu, Jing
Jiang, Wenli
Liu, Yi
Zeng, Rui
Wan, Zhi
Lei, Yi
Liao, Xiaoyang
author_facet Jia, Yu
Li, Dongze
You, Yi
Yu, Jing
Jiang, Wenli
Liu, Yi
Zeng, Rui
Wan, Zhi
Lei, Yi
Liao, Xiaoyang
author_sort Jia, Yu
collection PubMed
description BACKGROUND: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a newly defined condition encompassing hepatic steatosis and metabolic dysfunction. However, the relationship between MAFLD and multi-system diseases remains unclear, and the time-dependent sequence of these diseases requires further clarification. METHODS: After propensity score matching, 163,303 MAFLD subjects and 163,303 matched subjects were included in the community-based UK Biobank study. The International Classification of Diseases, Tenth Revision (ICD-10), was used to reclassify medical conditions into 490 and 16 specific causes of death. We conducted a disease trajectory analysis to map the key pathways linking MAFLD to various health conditions, providing an overview of their interconnections. RESULTS: Participants aged 59 (51–64) years, predominantly males (62.5%), were included in the study. During the 12.9-year follow-up period, MAFLD participants were found to have a higher risk of 113 medical conditions and eight causes of death, determined through phenome-wide association analysis using Cox regression models. Temporal disease trajectories of MAFLD were established using disease pairing, revealing intermediary diseases such as asthma, diabetes, hypertension, hypothyroid conditions, tobacco abuse, diverticulosis, chronic ischemic heart disease, obesity, benign tumors, and inflammatory arthritis. These trajectories primarily resulted in acute myocardial infarction, disorders of fluid, electrolyte, and acid–base balance, infectious gastroenteritis and colitis, and functional intestinal disorders. Regarding death trajectories of MAFLD, malignant neoplasms, cardiovascular diseases, and respiratory system deaths were the main causes, and organ failure, infective disease, and internal environment disorder were the primary end-stage conditions. Disease trajectory analysis based on the level of genetic susceptibility to MAFLD yielded consistent results. CONCLUSIONS: Individuals with MAFLD have a risk of a number of different medical conditions and causes of death. Notably, these diseases and potential causes of death constitute many pathways that may be promising targets for preventing general health decline in patients with MAFLD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-023-03080-6.
format Online
Article
Text
id pubmed-10590000
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105900002023-10-22 Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank Jia, Yu Li, Dongze You, Yi Yu, Jing Jiang, Wenli Liu, Yi Zeng, Rui Wan, Zhi Lei, Yi Liao, Xiaoyang BMC Med Research Article BACKGROUND: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a newly defined condition encompassing hepatic steatosis and metabolic dysfunction. However, the relationship between MAFLD and multi-system diseases remains unclear, and the time-dependent sequence of these diseases requires further clarification. METHODS: After propensity score matching, 163,303 MAFLD subjects and 163,303 matched subjects were included in the community-based UK Biobank study. The International Classification of Diseases, Tenth Revision (ICD-10), was used to reclassify medical conditions into 490 and 16 specific causes of death. We conducted a disease trajectory analysis to map the key pathways linking MAFLD to various health conditions, providing an overview of their interconnections. RESULTS: Participants aged 59 (51–64) years, predominantly males (62.5%), were included in the study. During the 12.9-year follow-up period, MAFLD participants were found to have a higher risk of 113 medical conditions and eight causes of death, determined through phenome-wide association analysis using Cox regression models. Temporal disease trajectories of MAFLD were established using disease pairing, revealing intermediary diseases such as asthma, diabetes, hypertension, hypothyroid conditions, tobacco abuse, diverticulosis, chronic ischemic heart disease, obesity, benign tumors, and inflammatory arthritis. These trajectories primarily resulted in acute myocardial infarction, disorders of fluid, electrolyte, and acid–base balance, infectious gastroenteritis and colitis, and functional intestinal disorders. Regarding death trajectories of MAFLD, malignant neoplasms, cardiovascular diseases, and respiratory system deaths were the main causes, and organ failure, infective disease, and internal environment disorder were the primary end-stage conditions. Disease trajectory analysis based on the level of genetic susceptibility to MAFLD yielded consistent results. CONCLUSIONS: Individuals with MAFLD have a risk of a number of different medical conditions and causes of death. Notably, these diseases and potential causes of death constitute many pathways that may be promising targets for preventing general health decline in patients with MAFLD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-023-03080-6. BioMed Central 2023-10-20 /pmc/articles/PMC10590000/ /pubmed/37864216 http://dx.doi.org/10.1186/s12916-023-03080-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Jia, Yu
Li, Dongze
You, Yi
Yu, Jing
Jiang, Wenli
Liu, Yi
Zeng, Rui
Wan, Zhi
Lei, Yi
Liao, Xiaoyang
Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank
title Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank
title_full Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank
title_fullStr Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank
title_full_unstemmed Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank
title_short Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank
title_sort multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the uk biobank
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590000/
https://www.ncbi.nlm.nih.gov/pubmed/37864216
http://dx.doi.org/10.1186/s12916-023-03080-6
work_keys_str_mv AT jiayu multisystemdiseasesanddeathtrajectoryofmetabolicdysfunctionassociatedfattyliverdiseasefindingsfromtheukbiobank
AT lidongze multisystemdiseasesanddeathtrajectoryofmetabolicdysfunctionassociatedfattyliverdiseasefindingsfromtheukbiobank
AT youyi multisystemdiseasesanddeathtrajectoryofmetabolicdysfunctionassociatedfattyliverdiseasefindingsfromtheukbiobank
AT yujing multisystemdiseasesanddeathtrajectoryofmetabolicdysfunctionassociatedfattyliverdiseasefindingsfromtheukbiobank
AT jiangwenli multisystemdiseasesanddeathtrajectoryofmetabolicdysfunctionassociatedfattyliverdiseasefindingsfromtheukbiobank
AT liuyi multisystemdiseasesanddeathtrajectoryofmetabolicdysfunctionassociatedfattyliverdiseasefindingsfromtheukbiobank
AT zengrui multisystemdiseasesanddeathtrajectoryofmetabolicdysfunctionassociatedfattyliverdiseasefindingsfromtheukbiobank
AT wanzhi multisystemdiseasesanddeathtrajectoryofmetabolicdysfunctionassociatedfattyliverdiseasefindingsfromtheukbiobank
AT leiyi multisystemdiseasesanddeathtrajectoryofmetabolicdysfunctionassociatedfattyliverdiseasefindingsfromtheukbiobank
AT liaoxiaoyang multisystemdiseasesanddeathtrajectoryofmetabolicdysfunctionassociatedfattyliverdiseasefindingsfromtheukbiobank